Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy
Cells · 20.02.2025 · 14 (5) · 320
DOI: 10.3390/cells14050320 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.02.2025. Verfasst von Bohan Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shan…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Antigens, Neoplasm, T-Lymphocytes. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the State Key Laboratory of Systems Medicine for Cancer, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) gene-modified T-cell therapy has achieved significant success in the treatment of hematological malignancies. However, this therapy has not yet made breakthroughs in the treatment of solid tumors and still faces issues of resistance and relapse in hematological cancers. A major reason for these problems is the antigenic heterogeneity of tumor tissues. This review outlines the antigenic heterogeneity encountered in CAR-T cell therapy and the corresponding strategies to address it. These strategies include using combination therapy to increase the abundance of target antigens, optimizing the structure of CARs to enhance sensitivity to low-density antigens, developing multi-targeted CAR-T cells, and reprogramming the TME to activate endogenous immunity. These approaches offer new directions for overcoming tumor antigenic heterogeneity in CAR-T cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200032, China.
- CARsgen Therapeutics, Shanghai 200231, China.
Förderung
- the National Natural Science Foundation of China
- the State Key Laboratory of Systems Medicine for Cancer
- National Natural Science Foundation of China
- State Key Laboratory of Systems Medicine for Cancer
Zitieren
APA
Zhang, B., Wu, J., Jiang, H., & Zhou, M. (2025). Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. Cells, 14(5), 320. https://doi.org/10.3390/cells14050320
Vancouver
Zhang B, Wu J, Jiang H, Zhou M. Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. Cells. 2025;14(5):320. doi:10.3390/cells14050320
BibTeX
@article{Zhang2025,
author = {Zhang, Bohan and Wu, Jiawen and Jiang, Hua and Zhou, Min},
title = {Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy},
journal = {Cells},
year = {2025},
volume = {14},
number = {5},
pages = {320},
doi = {10.3390/cells14050320}
}
EUVIMED